Release Date: December 23, 2025

Expiration Date: December 23, 2026

Activity Overview

This educational activity is an archive of the live presentation held on Monday, December 8, 2025.

For more information about this educational activity, the faculty, and disclosures, please click here.

Target Audience

This educational activity is primarily directed toward academic & community medical oncologists, APPs, oncology nurses, pharmacists, and other HCPs involved in the diagnosis and management of patients with breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Discuss current and emerging frontline and maintenance options for the management of HER2+ mBC
Develop tailored maintenance regimens for individual patients with HER2+ mBC to balance disease control with quality of life
Manage adverse effects associated with frontline treatments for HER2+ mBC

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

GET STARTED WITH THIS PROGRAM:

Create Account Already Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Pfizer, Inc.

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

GET STARTED WITH THIS PROGRAM:

Related Content